Lenacapavir for HIV prevention is a long-acting injectable PrEP option. The US FDA approved it for reducing the risk of sexually acquired HIV in eligible adults and adolescents in June 2025, and WHO recommended it as an additional prevention choice in July 2025. ^{[1] [2]}

This is general information and does not replace an individual PrEP assessment. Do not buy, start, stop, share, or change HIV prevention medicine on your own. Approval, availability, eligibility, and cost can differ by country and health system.

What is lenacapavir for HIV prevention?

Lenacapavir is a long-acting medicine offered as PrEP to people who do not have HIV and may benefit from additional prevention. Its long duration may help people who find daily tablets difficult because of routine, privacy, stigma, or access. ^{[2] [1]}

Does it completely prevent HIV?

No prevention method should be described as a guarantee for one person. Clinical studies found very high protection when the medicine and follow-up were used as intended, but HIV testing, timely appointments, and correct continuation remain essential. ^[1]

What must happen before starting?

Confirm that the person does not have HIV
Discuss the most recent possible exposure and any PEP or PrEP use
Review medicines, supplements, allergies, pregnancy, and health history
Confirm that the product is approved and available in the local service
Make a written plan for future injections and HIV testing

Why does follow-up matter?

Long-acting medicine remains in the body after an injection. Late follow-up or undiagnosed HIV can create safety concerns, including drug resistance. Contact the clinic early if an appointment may be missed; do not replace or extend protection with another product without advice. ^[1]

What does lenacapavir not prevent?

Lenacapavir PrEP does not prevent every STI or pregnancy. Condoms, appropriate STI testing, vaccination and contraception can be discussed according to personal needs; none should be presented as a universal package or guarantee. ^{[3] [4]}

Frequently asked questions

Is lenacapavir available everywhere?

No. Approval and implementation vary. Ask a local PrEP service rather than assuming US approval means immediate local access. ^[1]

Can it be used after a recent exposure?

PrEP is not a substitute for urgent PEP assessment after a recent possible exposure. Seek assessment as soon as possible and start when indicated within 72 hours, without waiting for symptoms or all laboratory results. If more time has passed, still seek assessment and a testing plan. ^[5]

Can someone stop attending after an injection?

No. HIV testing and planned follow-up remain important because the medicine is long acting. ^[1]

Summary

Lenacapavir adds a long-acting PrEP choice, not a universal or automatic option. Starting requires appropriate HIV testing and assessment, including the latest exposure and prevention medicine use, not just one early negative self-test. Follow-up and local availability must be confirmed with the provider. ^{[1] [6]}

Sources

หมายเหตุ บทความนี้ให้ข้อมูลความรู้ทั่วไป ไม่ใช่การวินิจฉัย และไม่ใช่คำแนะนำการใช้ยาเฉพาะบุคคล เรื่องยาและการรักษาเป็นการตัดสินใจร่วมกับแพทย์หรือเภสัชกรที่ดูแลคุณ ไม่ควรซื้อ เริ่ม หยุด หรือปรับยาด้วยตัวเอง หากมีข้อสงสัยเกี่ยวกับสุขภาพของตัวเอง ปรึกษาเจ้าหน้าที่สาธารณสุขหรือคลินิกใกล้บ้านได้เสมอ

อ้างอิงตามข้อความที่ตรวจทาน

ตรวจทานและปรับปรุงเนื้อหา: 24 ตุลาคม 2569